N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients

Journal of Proteome Research

Volumn 11, Issue 4, 2012, Pages 2282-2300

  Alley, William R ^a   Vasseur, Jacqueline A ^a   Goetz, John A ^a   Svoboda, Martin ^a   Mann, Benjamin F ^a   Matei, Daniela E ^b   Menning, Nancy ^b   Hussein, Ahmed ^a   Mechref, Yehia ^a   Novotny, Milos V ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

disease markers; exoglycosidase digestion; fucosylation; glycomics; IgG; ovarian cancer; permethylation

Indexed keywords

ANTINEOPLASTIC AGENT; FUCOSE; GLYCAN; IMMUNOGLOBULIN G;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUCOSYLATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SERUM; SIALYLATION;

TETRA;

EID: 84859560597     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr201070k     Document Type: Article

References (66)

1. Dube, D. H.; Bertozzi, C. R. Glycans in cancer and inflammation - potential for therapeutics and diagnostics Nat. Rev. Drug Discov. 2005, 4, 477-88
2. Varki, A. Biological roles of oligosaccharides: all of the theories are correct Glycobiology 1993, 3, 97-130
3. Ohtsubo, K.; Marth, J. D. Glycosylation in cellular mechanisms of health and disease Cell 2006, 126, 855-67
4. Arnold, J. N.; Saldova, R.; Hamid, U. M.; Rudd, P. M. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation Proteomics 2008, 8, 3284-93
5. Pan, S.; Chen, R.; Aebersold, R.; Brentnall, T. A. Mass spectrometry based glycoproteomics - from a proteomics perspective Mol. Cell. Proteomics 2011, 10, R110 003251
6. Reis, C. A.; Osorio, H.; Silva, L.; Gomes, C.; David, L. Alterations in glycosylation as biomarkers for cancer detection J. Clin. Pathol. 2010, 63, 322-9
7. Scholler, N.; Crawford, M.; Sato, A.; Drescher, C. W.; OBriant, K. C.; Kiviat, N.; Anderson, G. L.; Urban, N. Bead-based ELISA for validation of ovarian cancer early detection markers Clin. Cancer Res. 2006, 12, 2117-24
8. Patel, S.; Sumitra, G.; Koner, B. C.; Saxena, A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression Clin. Biochem. 2011, 44, 869-72
9. Yue, T.; Goldstein, I. J.; Hollingsworth, M. A.; Kaul, K.; Brand, R. E.; Haab, B. B. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays Mol. Cell. Proteomics 2009, 8, 1697-707
10. Weivoda, S.; Anderson, J. D.; Skogen, A.; Schlievert, P. M.; Fontana, D.; Schacker, T.; Tuite, P.; Dubinsky, J. M.; Jemmerson, R. J. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand J. Immunol. Methods 2008, 336, 22-9
11. Schorge, J. O.; Drake, R. D.; Lee, H.; Skates, S. J.; Rajanbabu, R.; Miller, D. S.; Kim, J. H.; Cramer, D. W.; Berkowitz, R. S.; Mok, S. C. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer Clin. Cancer Res. 2004, 10, 3474-8
12. Blixt, O.; Head, S.; Mondala, T.; Scanlan, C.; Huflejt, M. E.; Alvarez, R.; Bryan, M. C.; Fazio, F.; Calarese, D.; Stevens, J.; Razi, N.; Stevens, D. J.; Skehel, J. J.; van Die, I.; Burton, D. R.; Wilson, I. A.; Cummings, R.; Bovin, N.; Wong, C. H.; Paulson, J. C. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17033-8
13. Chen, P.; Liu, Y.; Kang, X.; Sun, L.; Yang, P.; Tang, Z. Identification of N-glycan of alpha-fetoprotein by lectin affinity microarray J. Cancer Res. Clin. Oncol. 2008, 134, 851-60
14. Jacob, F.; Goldstein, D. R.; Bovin, N. V.; Pochechueva, T.; Spengler, M.; Caduff, R.; Fink, D.; Vuskovic, M. I.; Huflejt, M. E.; Heinzelmann-Schwarz, V. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array Int. J. Cancer 2012, 130, 138-46
15. Liang, C. H.; Wu, C. Y. Glycan array: a powerful tool for glycomics studies Expert Rev. Proteomics 2009, 6, 631-45
16. Lu, K. H.; Patterson, A. P.; Wang, L.; Marquez, R. T.; Atkinson, E. N.; Baggerly, K. A.; Ramoth, L. R.; Rosen, D. G.; Liu, J.; Hellstrom, I.; Smith, D.; Hartmann, L.; Fishman, D.; Berchuck, A.; Schmandt, R.; Whitaker, R.; Gershenson, D. M.; Mills, G. B.; Bast, R. C., Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis Clin. Cancer Res. 2004, 10, 3291-300
17. Reid, J. D.; Parker, C. E.; Borchers, C. H. Protein arrays for biomarker discovery Curr. Opin. Mol. Ther. 2007, 9, 216-21
18. Duffy, M. J.; Bonfrer, J. M.; Kulpa, J.; Rustin, G. J.; Soletormos, G.; Torre, G. C.; Tuxen, M. K.; Zwirner, M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Int. J. Gynecol. Cancer 2005, 15, 679-91
19. Badgwell, D.; Bast, R. C., Jr. Early detection of ovarian cancer Dis. Markers 2007, 23, 397-410
20. Bast, R. C., Jr.; Badgwell, D.; Lu, Z.; Marquez, R.; Rosen, D.; Liu, J.; Baggerly, K. A.; Atkinson, E. N.; Skates, S.; Zhang, Z.; Lokshin, A.; Menon, U.; Jacobs, I.; Lu, K. New tumor markers: CA125 and beyond Int. J. Gynecol. Cancer 2005, 15 (Suppl 3) 274-81
21. Arnold, J. N.; Royle, L.; Dwek, R. A.; Rudd, P. M.; Sim, R. B. Human immunoglobulin glycosylation and the lectin pathway of complement activation Adv. Exp. Med. Biol. 2005, 564, 27-43
22. Abd Hamid, U. M.; Royle, L.; Saldova, R.; Radcliffe, C. M.; Harvey, D. J.; Storr, S. J.; Pardo, M.; Antrobus, R.; Chapman, C. J.; Zitzmann, N.; Robertson, J. F.; Dwek, R. A.; Rudd, P. M. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression Glycobiology 2008, 18, 1105-18
23. Saldova, R.; Royle, L.; Radcliffe, C. M.; Abd Hamid, U. M.; Evans, R.; Arnold, J. N.; Banks, R. E.; Hutson, R.; Harvey, D. J.; Antrobus, R.; Petrescu, S. M.; Dwek, R. A.; Rudd, P. M. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG Glycobiology 2007, 17, 1344-56
24. Saldova, R.; Wormald, M. R.; Dwek, R. A.; Rudd, P. M. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis Dis. Markers 2008, 25, 219-32
25. Andersen, J. D.; Boylan, K. L.; Xue, F. S.; Anderson, L. B.; Witthuhn, B. A.; Markowski, T. W.; Higgins, L.; Skubitz, A. P. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis Electrophoresis 2010, 31, 599-610
26. Kang, P.; Madera, M.; Alley, W. R., Jr.; Goldman, R.; Mechref, Y.; Novotny, M. V. Glycomic alterations in the highly-abundant and lesser-abundant blood serum protein fractions for patients diagnosed with hepatocellular carcinoma Int. J. Mass Spectrom. 2011, 305, 185-98
27. Goldman, R.; Ressom, H. W.; Varghese, R. S.; Goldman, L.; Bascug, G.; Loffredo, C. A.; Abdel-Hamid, M.; Gouda, I.; Ezzat, S.; Kyselova, Z.; Mechref, Y.; Novotny, M. V. Detection of hepatocellular carcinoma using glycomic analysis Clin. Cancer Res. 2009, 15, 1808-13
28. Callewaert, N.; Van Vlierberghe, H.; Van Hecke, A.; Laroy, W.; Delanghe, J.; Contreras, R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics Nat. Med. 2004, 10, 429-34
29. Kyselova, Z.; Mechref, Y.; Kang, P.; Goetz, J. A.; Dobrolecki, L. E.; Sledge, G. W.; Schnaper, L.; Hickey, R. J.; Malkas, L. H.; Novotny, M. V. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles Clin. Chem. 2008, 54, 1166-75
30. Alley, W. R., Jr.; Madera, M.; Mechref, Y.; Novotny, M. V. Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery Anal. Chem. 2010, 82, 5095-106
31. Mechref, Y.; Hussein, A.; Bekesova, S.; Pungpapong, V.; Zhang, M.; Dobrolecki, L. E.; Hickey, R. J.; Hammoud, Z. T.; Novotny, M. V. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets J. Proteome Res. 2009, 8, 2656-66
32. Kyselova, Z.; Mechref, Y.; Al Bataineh, M. M.; Dobrolecki, L. E.; Hickey, R. J.; Vinson, J.; Sweeney, C. J.; Novotny, M. V. Alterations in the serum glycome due to metastatic prostate cancer J. Proteome Res. 2007, 6, 1822-32
33. Jacobs, I.; Bast, R. C., Jr. The CA 125 tumour-associated antigen: a review of the literature Hum. Reprod. 1989, 4, 1-12
34. Jankovic, M. M.; Milutinovic, B. S. Glycoforms of CA125 antigen as a possible cancer marker Cancer Biomark. 2008, 4, 35-42
35. Kong, F.; White, C. N.; Xiao, X.; Feng, Y.; Xu, C.; Xe, D.; Zhang, Z.; Yu, Y. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer Gynecol. Onocol. 2006, 100, 247-53
36. Kozak, K. R.; Su, F.; Whitelegge, J. P.; Faull, K.; Reddy, S.; Farias-Eisner, R. Characterization of serum biomarkers for detection of early stage ovarian cancer Proteomics 2005, 5, 4589-96
37. Li, B.; An, H. J.; Kirmiz, C.; Lebrilla, C. B.; Lam, K. S.; Miyamoto, S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins J. Proteome Res. 2008, 7, 3776-88
38. Lin, Y. W.; Lin, C. Y.; Lai, H. C.; Chiou, J. Y.; Chang, C. C.; Yu, M. H.; Chu, T. Y. Plasma proteomic pattern as biomarkers for ovarian cancer Int. J. Gynecol. Cancer 2006, 16 (Suppl 1) 139-46
39. Mor, G.; Visintin, I.; Lai, Y.; Zhao, H.; Schwartz, P.; Rutherford, T.; Yue, L.; Bray-Ward, P.; Ward, D. C. Serum protein markers for early detection of ovarian cancer Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7677-82
40. An, H. J.; Miyamoto, S.; Lancaster, K. S.; Kirmiz, C.; Li, B.; Lam, K. S.; Leiserowitz, G. S.; Lebrilla, C. B. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer J. Proteome Res. 2006, 5, 1626-35
41. Leiserowitz, G. S.; Lebrilla, C.; Miyamoto, S.; An, H. J.; Duong, H.; Kirmiz, C.; Li, B.; Liu, H.; Lam, K. S. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int. J. Gynecol. Cancer 2008, 18, 470-5
42. Matei, D.; Emerson, R. E.; Schilder, J.; Menning, N.; Baldridge, L. A.; Johnson, C. S.; Breen, T.; McClean, J.; Stephens, D.; Whalen, C.; Sutton, G. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial Cancer 2008, 113, 723-32
43. Kang, P.; Mechref, Y.; Klouckova, I.; Novotny, M. V. Solid-phase permethylation of glycans for mass spectrometric analysis Rapid Commun. Mass Spectrom. 2005, 19, 3421-8
44. McGill, R.; Tukey, J. W.; Larsen, W. A. Variations of Box Plots Am. Stat. 1978, 32
45. Swets, J. A. Measuring the accuracy of diagnostic systems Science 1988, 240, 1285-93
46. Mann, B.; Madera, M.; Sheng, Q.; Tang, H.; Mechref, Y.; Novotny, M. V. ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics Rapid Commun. Mass Spectrom. 2008, 22, 3823-34
47. Abbott, K. L.; Nairn, A. V.; Hall, E. M.; Horton, M. B.; McDonald, J. F.; Moremen, K. W.; Dinulescu, D. M.; Pierce, M. Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer Proteomics 2008, 8, 3210-20
48. Abbott, K. L.; Lim, J. M.; Wells, L.; Benigno, B. B.; McDonald, J. F.; Pierce, M. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis Proteomics 2010, 10, 470-81
49. Anderson, N. L.; Anderson, N. G. The Human Plasma Proteome Mol. Cell. Proteomics 2002, 1, 845-867
50. Azuma, Y.; Murata, M.; Matsumoto, K. Alteration of sugar chains on alpha(1)-acid glycoprotein secreted following cytokine stimulation of HuH-7 cells in vitro Clin. Chim. Acta 2000, 294, 93-103
51. Higai, K.; Miyazaki, N.; Azuma, Y.; Matsumoto, K. Interleukin-1beta induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene FEBS Lett. 2006, 580, 6069-75
52. Katnik, I.; Jadach, J.; Krotkiewski, H.; Berber, J. Investigating the glycosylation of normal and ovarian cancer haptoglobins using digoxigenin-labelled lectins Glycoconjucate J. 1984, 97-104
53. Thompson, S.; Dargan, E.; Turner, G. A. Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer Cancer Lett. 1992, 66, 43-8
54. Thompson, S.; Turner, G. A. Elevated levels of abnormally-fucosylated haptoglobins in cancer sera Br. J. Cancer 1987, 56, 605-10
55. Lin, Z.; Simeone, D. M.; Anderson, M. A.; Brand, R. E.; Xie, X.; Shedden, K. A.; Ruffin, M. T.; Lubman, D. M. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer J. Proteome Res. 2011, 10, 2602-11
56. Arnold, J. N.; Saldova, R.; Galligan, M. C.; Murphy, T. B.; Mimura-Kimura, Y.; Telford, J. E.; Godwin, A. K.; Rudd, P. M. Novel glycan biomarkers for the detection of lung cancer J. Proteome Res. 2011, 10, 1755-64
57. Takeda, Y.; Shinzaki, S.; Okudo, K.; Moriwaki, K.; Murata, K.; Miyoshi, E. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012, in press.
58. Fujimura, T.; Shinohara, Y.; Tissot, B.; Pang, P. C.; Kurogochi, M.; Saito, S.; Arai, Y.; Sadilek, M.; Murayama, K.; Dell, A.; Nishimura, S.; Hakomori, S. I. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects Int. J. Cancer 2008, 122, 39-49
59. Park, S. Y.; Yoon, S. J.; Jeong, Y. T.; Kim, J. M.; Kim, J. Y.; Bernert, B.; Ullman, T.; Itzkowitz, S. H.; Kim, J. H.; Hakomori, S. I. N-glycosylation status of beta-haptoglobin in sera of patients with colon cancer, chronic inflammatory diseases and normal subjects Int. J. Cancer 2010, 126, 142-55
60. Hoagland, L. F. t.; Campa, M. J.; Gottlin, E. B.; Herndon, J. E., 2nd; Patz, E. F., Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer Cancer 2007, 110, 2260-8
61. Yamashita, K.; Koide, N.; Endo, T.; Iwaki, Y.; Kobata, A. Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma J. Biol. Chem. 1989, 264, 2415-23
62. Debruyne, E. N.; Vanderschaeghe, D.; Van Vlierberghe, H.; Vanhecke, A.; Callewaert, N.; Delanghe, J. R. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients Clin. Chem. 2010, 56, 823-31
63. Gercel-Taylor, C.; Bazzett, L. B.; Taylor, D. D. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer Gynecol. Oncol. 2001, 81, 71-6
64. Kanoh, Y.; Mashiko, T.; Danbara, M.; Takayama, Y.; Ohtani, S.; Egawa, S.; Baba, S.; Akahoshi, T. Changes in serum IgG oligosaccharide chains with prostate cancer progression Anticancer Res. 2004, 24, 3135-9
65. Matsumoto, A.; Shikata, K.; Takeuchi, F.; Kojima, N.; Mizuochi, T. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation J. Biochem. 2000, 128, 621-8
66. Lattova, E.; Tomanek, B.; Bartusik, D.; Perreault, H. N-glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with herceptin and herceptin/Lipoplex J. Proteome Res. 2010, 9, 1533-40